Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Radium-223 dichloride (Xofigo, BAY 88-8223);   Drug: Pembrolizumab Sponsor:   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials